United States Environmental Protection Agency Chemical Safety and Pollution Prevention (7101) EPA 712
- [insert number] DRAFT 6
- 2 9
- 1 1 

# Product Performance **Test Guidelines** O CSPP 810. 2 7 00 : Products with Prion

Related Claims2 **NOTICE** This guideline is one of a series of test guidelines established by the Office of Prevention, Pesticides and Toxic Substances (OPPTS), United States Environmental Protection Agency for use in testing pesticides and chemical substances to develop data for s ubmission to the Agency under the Toxic Substances Control Act (TSCA) (15 U.S.C. 2601, et seq. ), the Federal Insecticide, Fungicide , and Rodenticide Act (FIFRA) (7 U.S.C. 136, et seq. ), and section 408 of the Federal Food, Drug and Cosmetic (FFDCA) (21 U.S.C. 346a). The OPPTS test guidelines serve as a compendium of accepted scientific methodologies and protocols that are intended to provide data to inform regulatory decisions under TSCA, FIFRA and /or FFDCA. This document provides guidance for conducting the test, and is also used by EPA, the public and the companies that are subject to data submission requirements under TSCA, FIFRA and/or the FFDCA. As a guidance document, these guidelines are no t binding on either EPA or any outside parties, and the EPA may depart from the guidelines where circumstances warrant and without prior notice. At places in this guidance, the Agency uses the word “should.” In this guidance, u se of “should” with regard to an action means that the action is recommended rather than mandatory

. The procedures contained in this guideline are strongly recommended for generating the data that are the subject of the guideline, but EPA recognizes that departures may be approp riate in specific situations. You may propose alternatives to the recommendations described in these guidelines, and the Agency will assess them for appropriateness on a case
- by
- case basis. For additional information about OPPTS harmonized test guidelin es and to access the guidelines electronically, please go to http://www.epa.gov/oppts and select “Test Methods & Guidelines” on the left side navigation menu. You may also access the guidelines in http://www.regulations.gov grouped by Series under Docket ID #s: EPA
- HQ
- OPPT
- 2009
- 0150 through EPA
- HQ
- OPPT
- 2009
- 0159, and EPA
- HQ
- OPPT
- 2009
- 0576.
**DRA FT DOCUMENT DISCLA** **IMER:** T his draft document is distributed solely for the purpose of external review. I t has not been formally disseminated by the EPA and should not be construed to represent any Agency determination or policy. The information correction process under the Agency’s Information Quality Guidelines does not apply until this document is formall y disseminated by the EPA in its final form. This draft document should only be cited or quoted in the context of providing comments.3

**OPPTS 810.**  **2400 :**  **Products w ith Prion**  **- Related Claims**  **.** (a) **Scope**

— (1) **Ap plicability**  **.** This guideline describes test methods that EPA believes will generally satisfy certain testing requirements of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) (7 U.S.C. 136, et seq. ), and the Federal Food, Drug, and Cosmetic Act (FFDCA) (21 U.S.C., 301 et seq. ). (2) **Background.** Pr

ion (“ **pr**oteinaceous **in** fectious particle”) is a term often used to designate an infectious agent that causes progressive degenerative diseases of the central nervous system , which are collectively called the transmissible spongiform encephalopathies ( TSEs o r prion diseases ) , including scrapie, chronic wasting disease (CW D) , bovine spongiform encephalopathy (BSE) , and various forms of Creutzfeldt
- Jakob disease (CJD) , etc. These infectious particles, which accumulate in brain tissue during the incubation periods of TSEs, are comprised of abnormal folding conformations of a normal, ubiquitous protein called the “cellular” prion protein ( PrP C ). This normal cellular prion protein is synthesized and eventually degraded thro ugh normal metabolic processes

. I n certain instances , however, protein molecules may become misfolded. Wh en prion proteins misfold (hereafter called “prions”) , t he resultant shape change serves as a template to induce the misfolding of the normal cellular prion protein to produce more infe ctious prions and, thereby, propagate an infection

. T he se abnormal prion s resist proteosomal degradation and slow ly accumulate in the brain and infect brain tissue

. The first described prion disease was scrapie, and so such infectious proteins are often designated collectively as PrP Sc in all TSEs. Some scientists prefer to use other terms such as P r P res , PrP d , PrP TSE , PrP CWD , and PrP CJD to designate the specific , abnormal forms of PrP associated with specific prion diseases

. For purposes of this guidance, the terms “prions” and “TSE agents” are synonymous. These abnormal prion proteins, although somewhat variable, share properties that distinguish them from normal PrP C : they are usually insoluble in non - denaturing detergent
- salt solutions and relatively resistant to digestion with the enzyme proteinase K. These properties are attributed to misfolding of PrP C to yield isoforms that are enriched in beta
- sheet secondary structure

. Many scientific experts have conclu ded that the abnormal prion proteins themselves are the self
- replicating infectious agents causing TSEs (Prusiner 1982, 2004); however, t here remain notable reservations , as outlined by Manuelidis ( 2007a, b)

. 1. Manuelidis L. 2007a. A 25 nm virion is the likely cause of transmissible spongiform encephalopathies. Journal of cellular biochemistry; 100(4):897
- 915. 2. Manuelidis L, Yu ZX, Barquero N, Mullins B. 2007b. Cells infected with scrapie and Creutzfeldt
- Jakob disease agents produce intracellular 25
- nm virus
- like particles.4 Proceedings of the National Academy of Sciences of the United States of America; 104(6):1965
- 70. 3. Prusiner SB. 1982. Novel proteinaceous infectious particles cause scrapie. Science; 216:136
-44. 4. Prusiner SB. 2004. D etecting mad cow disease. Scientific American; 291(1):86
- 93. **(b) Purpose.** This guideline provides pesticide applicants and registrants guidance on test systems and performance standards that apply to pesticide products intended to reduce the infectivity of prions on inanimate, environmental surfaces (hereafter called
“ prion
- related products ”) . EPA encourages pesticide applicants and registrants to follow this guidance and submit a draft test protocol to EPA for review prior to conducting any studies. EPA may revise this guidance over time, as needed, to reflect advances in available test methods and scientific knowledge pertaining to prions. S tudies conducted under this guideline are to be completed under EPA’s Good Laboratory Practice regulations (40 CFR Part 160). **(c) Guidance** 

— **(1) Label**  **ing Claims**  **.** Testing conducted according to c urrently available test methods are adequate for measuring reduction in prion infectivity, but not for demonstrating complete destruction or inactivation of prions. Accordingly, claims such as “inactivates,” “destroys,” “denatures” and “eliminates” are not supported by currently available test methods . Further, a prion
- related claim should include the type of prion ag ainst which the product has been successfully tested

. Assuming acceptable data were available, the following is the general format for a claim that EPA may consider accepting :

“ Has been demonstrated to reduce infectivity of prions (TSE agents) by (X) logs (insert log reduction number supported by data) based on a bioassay of the (insert prion type) in (insert type of organism in which the prions were tested ) .” A n example of a claim that EPA could find to be acceptable depending on supporting data would be: “Has been demonstrated to reduce infectivity of prions (TSE agents) by six ( 6 ) logs based on a bioassay of the scrapie prion in transgenic mice .” **(2) Selecting a Test System .**  The test system should be appropriate to the uses that appear on the proposed label.
**a. Carrier** **- based Method** 

. If the intended uses of a product are for reducing the infectivity of prions on inanimate surfaces, then a carrier
- based, animal bioassay should be used to measure the amount of prion infectivity reductio n that is achieved by the product when used according to label directions

. Examples of published, carrier
- based test methods include:5 1. Lemmer K, Mielke M, Kratzel C, Joncic M, Oezel M, Pauli G, Beekes M. Decontamination of surgical instruments from prions. II. In vivo findings with a model system for testing the removal of scrapie infectivity from steel surfaces. J Gen Virol. 2008 Jan;89(Pt 1):348
- 58. 2. Peretz D, Supattapone S, Giles K, Vergara J, Freyman Y, Lessard P, Safar JG, Glidden DV, McCulloch C, Nguyen H
- OB, Scott M, DeArmond SJ, and Prusiner SB. 2006. Inactivation of prions by sodium dodecyl sulfate. J. Virol. 80:322
- 331. 3. We issmann C, Enari M, Klohn PC, Rossi P, Flechsig E. 2002. Transmission of pr ions. J Infect Dis 186 Suppl 2:S157
- 65. 4. Zobeley E, Flechsig E, Cozzio A, Enari M, and W eissman C. 1999. Infectivity of scrapie prions bound to a stainless steel surface. Molecular Medicine 5:240
- 243. **b. Suspension**  **- based Test Method**  **.** If the intend ed use of a product includes only treating liquids (e.g., liquid wastes), then a suspension
- based, animal bioassay should be used to measure the amount of prion infectivity reduction that is achieved by the product when used according to label directions. An example of a published, suspension
- based test method is : 1. Peretz D, Supattapone S, Giles K, Vergara J, Freyman Y, Lessard P, Safar JG, Glidden DV, McCulloch C, Nguyen H
- OB, Scott M, DeArmond SJ, and Prusiner SB. 2006. Inactivation of prions by s odium dodecyl sulfate. J. Virol. 80:322
- 331. **(3) Methods of Estimating the Reduction of Prion Infectivity**  **.** Prion diseases are generally characterized by a long asymptomatic incubation period , followed by the rapid onset of symptoms , followed by death. The length of the incubation period is reproducible upon repeated passages of a given prion and is inversely proportional to the log of the infectious dose of that prion , although at both very high and very low concentrations of infect ivity the relationship is no longer linear. Two methods of estimating the reduction of prion infectivity have been employed: **endpoint titration** and **incubation time interval assay**

. The former method may be best suited to analyze suspension
- based testing and the latter may be best suited for carrier
- based testing

. Further , incubation time interval assays are generally not quite as accurate as endpoint titration assays (0.5 log difference 1 ) , and may be less reliable for quantifying very low levels of infectivity.
**a. End**  **- point Titration**  **.** An end
- point titration is a classical method of determining the titer of a sample (i.e., the concentration of the pathogen ) . To

1 Prusiner SB, Cochran SP, Downey DE, Groth DF. Determination of scrapie agent titer from incubation period measurements in hamsters. Adv. Exp. Med. Biol. 1981;134:385
- 99. Prusiner SB, Cochran SP, Groth DF, Downey DE, Bowman KA, Martinez HM. Measurement of the scrapie agent using an incubation time interval assay. Ann. Neurol. 1982 Apr;11(4):353
- 8.6

begin with, a sample is serially diluted by a factor of 10 until less than 1 ID 50 (the infectious dose which kills 50% of the pathogen) remains in the final dilution. The resulting set of serial dilutions is used to inoculate a corresponding set of experimental animals, typically at least four animals per 10
-fold dilution. The experim ental animals are observed for the appearance of symptoms , and t he symptoms are scored. The animals are observed for a predetermined period, usually 450 days for hamsters or 500 days for mice. At the end of the predetermined period, any surviving animals would be humanely euthanized before they would die of the prion disease and given a thorough neuropathological examination that looks for signs of prion disease as described in section (4 ) below. The titer may be determined by several statistical methods (see references below). The titers of subsequent samples are determined in the same fashion. The following are examples of end
- point titration methods:

1. Andersen J, Barrett T, Scott GR. 1996. Appendix 3. Fifty percent effective dose (ED 50 ): Spe arman - Kärber method. In Manual of the Diagnosis of Rinderpest. (FAO Animal Health Manual

– 1) Food and Agriculture Organization of the United Nations. Rome. Available on
- line: http://www.fao.org/docrep/w0049e/w0049e07.htm#appendix%203.%20fift y%20percent%20effective%20dose%20(ed50):%20spearman%20kärber %20method 2. Reed LJ and Muench H. A simple method for estimating fifty percent endpoints. Amer J Hyg 1938;27:493
- 7. 3. Bliss CI. The method of probits. Science. 1934 Jan 12;79(2037):38
- 39

. **b. Incubation Time Interval**  **As say**  **.** An incubation time interval assay exploits the relationship between th e length of the incubation period and the titer of the pathogen in an inoculum. An endpoint titration of a starting brain homogenate is used to establish an empirical relationship between prion titer and length of incubation period. Once the relationship is established, the titer of any subsequent sample is determined by observing the incubation period of an inoculated animal group (usually at least four) and using this value to predict a corresponding titer based on the empirically determined relationshi p. The initial endpoint titration should not be greatly, if at all, separated in time from the experimental assay. If the initial endpoint titration is to be replaced with historical animal model data , then sufficient control animals should be included to e nsure that the historical animal model data are relevant to the experimental assay. The following are examples of incubation time interval assay methods: 1. Prusiner SB, Cochran SP, Groth DF, Downey DE, Bowman KA, Martinez HM. 1982. Measurement of the scrapie agent using an incubation time interval assay. Ann. Neurol. April;11(4):353
- 8.7 2. Prusiner SB, Cochran SP, Downey DE, Groth DF. 1981. Determination of scrapie agent titer from incubation period measurements in hamsters. Adv Exp Med Biol. 134:385
- 99. The endpoint titration and incubation time interval assays yield similar results ; however, the endpoint titration requires many more animals. As a result, the incubation time interval assay is the mo re widely used assay method for prions sin ce it is faster, uses fewer animals , and provides results that are negligibl y different ( ± 0.5 log ) 2 compared to the endpoint titration. However, an endpoint titration assay may be more useful than an incubation time assay if the difference between the titer of the prions in the starting inoculum and the treated carrier is very high or very low , or if one wants to directly compare two samples with similar titers

. A comparison of the number of animals required for these assays is listed in Appendix 1 . T he 263K strain of hamster
- adapted scrapie is being provided as an example . The endpoint titration requires between two and four times the animals as the incubation time interval assay

. **c. Other Relevant Tests.** EPA welcomes data from screening tests ( such as We stern blot, ELISA, Protein Misfolding Cyclic Amplification (PMCA), or cell culture assays), but such tests are not a substitute for the suspension
- based or carrier
- based tests . **(4) Other important aspects of the test sy** **stem include the following :**  **T iter of prions**  **:** Depending on the test method and type of prion used, the titer of the prions in the initial inoculum may range from 10 4 to 10 11 ID 50 units/g of brain homogenate , based on currently available studies . After dilution and drying of the inoculum on the carrier or in a suspension, the titer of the prions may be further reduced by 1
- 2 logs. The study should have a reliable method for determining the concentration of prions in the initial inoculum and the concentration of prions dried on the carrier or mixed in a suspension. The dynamic range of the test method’s ability to measure reduction in infectivity should be well established. In order for the test to be able to measure at least a six ( 6 ) log redu ction in infectivity [see section (5) Evaluation of Success below] , the titer of the prions on the carrier or in a suspension (i.e., the titer to which test animals will be exposed) should be at least 10 7 ID 50 units/g brain homogenate (or about 10 9 ID 50 un its/g brain homogenate in the initial inoculum). Finally, the protocol should address and balance such issues as the preparation of the initial inoculum, the order in which animals are inoculated, and how the animals are housed (see Animal Housing below). **Prion type**  **:** Several types of prions are available for use in infectivity tests, such as scrapie prions (hamster adapted 263K), BSE prions (mouse adapted 301V, 310C and 6BP1), and sCJD prions (human). An animal
- related prion (e.g., scrapie, CWD ) should be selected for testing if the proposed use sites are animal
- related (e.g., farm premises, farm equipment, veterinary clinics). A human
- related prion (e.g., sCJD) should be selected if the proposed use sites

2 See references in footnote 1.8

are related to hum ans (e.g., surgical instruments, hospital rooms, laboratories). [Note: Prospective registrants should consult with the U.S. Food and Drug Administration (FDA) for uses that are also under its jurisdiction (e.g., medical devices or adjuncts to medical dev ices). The FDA considers claims of activity against prions (TSE agents) to be unique and unclassified, and recommends that product manufacturers seeking a product claim of reducing the infectivity of prions (TSE agents) for any healthcare use meet with FD A to learn the FDA’s recommendations for seeking product approval.] H uman - derived TSE materials of a known titer currently are available at only a few research laboratories

. **Age of test animals at beginning of study :**  Animals should be old enough to tole rate intracerebral inoculation without excessive mortality , i.e., in the following age ranges : mice , 6
- 10 weeks old; hamsters , 5
- 8 weeks old; and guinea pigs , 5
- 7 weeks old . The study should continue up to the end of the animals’ normal life span (the poi nt at which normal mortality begins to increase significantly). Historical mortality data on the selected strain of test animals should be provided to substantiate the selection of these critical lifespan points. **Number of animals :**  The numbers of anim als in the treatment and control groups should be sized based on statistical validity, and the calculations supporting the proposed animal group sizes should be included. The number of animals typically used is between 4 and 24

. **Types /Species**  **of animals :**  The type/species of animal is determined by the test method selected. The test animals are either genetically homogeneous mice or hamsters, or transgenic (genetically altered to express the prion protein

— PrP

— of the host animal) mice or hamsters. If the animals are transgenic, the test protocol should identify the source of the transgenic gene material and available information that characterizes it. Native species of prions may also be tested in relevant animal species. **Animal housing and environme** **ntal conditions :**  The number of animals per cage should be kept to a minimum and the cages should be compatible with the animals. Other animal housing issues should be addressed to avoid influencing the test results; for example, such as which groups may be housed next to each other, and rotating cages to balance exposure to heat, light, noise, etc. Transgenic or wild
-ty pe mice can be housed 5
- 8 per cage, depending on the size of the cage, and hamsters are generally housed two per cage. The temperature i n the experimental animal room should be 22°C (± 3°C). The relative humidity should be at least 30% and preferably not exceed 70% other than during room cleaning. Lighting should be artificial, the sequence being 12 hours light and 12 hours dark. **Lengt h of study** **:** The study should be extended as long as possible, taking into account the historical mortality data for the particular animal type/species used. Transgenic or wild
-ty pe mice should be kept for 500 days. Hamsters should be kept for 4 5 0 days.9

**Examination of animals at end of study or when animals die prematurely :**  Wh en animals reach the defined age limit or die prematurely, tests should be performed on all members of both the treated and control groups, in order to ascertain whether they are infected with prions. Such tests should include at least one of the following: W estern blot, immunological histochemistry or “blind passage.” The method for dealing with premature deaths and how to place them into the statistical calculations should als o be addressed in the statistical evaluation plan for the study. **Evaluation of Success :**  The target criterion for success is no less than six ( 6 ) logs of reduction of infectivity in the treated versus untreated (control) groups. **Submission of Draft Protocol:**  Due to the wide variety of available animal bioassays for measuring reduction of prion infectivity by a prion
- related product on environmental surfaces, t he Agency strongly recommends that the registrant submit a draft test protocol to EPA for review prior to conducting such a study. The Agency also recommends that the registrant request a pre
- registrati on conference to discuss registration data and labeling requirements for a prion
related product.10

**Ap pendix 1. A** **nimals used in an endpoint ti tration versus an incubation time interval**  **assay under different sets of assumptions**  **As suming:** 

 Initial brain titer of 10 10 ID 50/g  10 treatments are evaluated.  6 animals are used per log dilution.  Each treatment reduces infectivity by 10 4

. **Endpoint titration:**  Initial titration (10 log dilutions) 10 x 6 = 60 10 x Titration of each treatment (7 log dilutions) 10 x 7 x 6 = 420 Total 480 **Incubation time interval assay :**  Titration/calibration curve (10 log dilutions) 10 x 6 = 60 10 x 1 group per treatment 10 x 6 = 60 Total 120 **Same assumptions except:**

 Each treatment reduces infectivity by 10 6

. **Endpoint titration:** Initial titration (10 log dilutions) 10 x 6 = 60 10 x Titration of each treatment (5 log dilutions) 10 x 5 x 6 = 300 Total 360 **Incubation time interval assay :**  Titration/calibration curve (10 log dilutions) 10 x 6 = 60 10 x 1 group per treatment 10 x 6 = 60 Total 120 **Same assumpti ons except:** 

 Each treatment reduces infectivity by 10 8

. **Endpoint titration:** Initial titration (10 log dilutions) 10 x 6 = 60 10 x Titration of each treatment (3 log dilutions) 10 x 3 x 6 = 180 Total 240 **Incubation time interva l assay**  **:** Titration/calibration curve (10 log dilutions) 10 x 6 = 60 10 x 1 group per treatment 10 x 6 = 60 Total 120